ArticleDigital health
Validity of a smartphone application for self-monitoring psychiatric symptoms in patients with schizophrenia.
Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Chatbot Remote Monitoring System in Patients with Schizophrenia: A Pilot Study of User Experience.Consortium psychiatricum · 2026Article
- AI-enabled passive digital phenotyping of experiential negative symptoms in schizophrenia-spectrum disorders: a narrative review on the path from sensing to clinical endpoints.Frontiers in psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Despite increasing research on digital technologies for psychiatric disorders, studies specifically examining self-monitoring of symptoms with smartphone applications by patients with schizophrenia remain limited. This study aims to evaluate the validity and reliability of self-monitoring psychiatric symptoms using a smartphone application among patients with schizophrenia at Mindlink, a community-based early intervention center. Methods: Fifty-three young patients with schizophrenia spectrum disorders participated. They rated their psychiatric symptoms across five domains-delusions, hallucinations, anxiety, depression, and perceived stress-using an 11-point Likert scale at baseline, 1 week, 8 weeks, and 16 weeks. Test-retest reliability was assessed using intraclass correlation coefficients (ICCs) between baseline and 1-week ratings. Concurrent validity was determined by correlating app-based ratings with established self-report and clinician-administered scales, including the Eppendorf Schizophrenia Inventory, Hamilton Program for Schizophrenia Voices Questionnaire, Beck Depression Inventory, Generalized Anxiety Disorder-7, and Perceived Stress Scale. The accuracy of the app's depression rating was assessed using receiver operating characteristic (ROC) analysis. Results: ICCs for test-retest reliability were high across all symptom domains, ranging from 0.741 to 0.876 ( Conclusion: This study demonstrates that self-monitoring of key symptoms and stress using a smartphone application is valid and reliable for patients with schizophrenia. These findings support the app's potential to enhance symptom management and enable early detection of relapse in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.